EUCTR2008-004455-29-DE进行中（未招募）不适用
A phase II, randomized, multicentre, observer-blind study to compare and characterize the immunoginicity and safety parameters induced by various GSK Biologicals’ Adjuvant Systems in combination with the Hepatitis B surface antigen (HBsAg), according to a 0, 1 month schedule with a booster at Month 12, in healthy, Hepatitis B virus (HBV) naïve, adults. - EARLY-CLINRES-002
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 710
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All Subjects must satisfy the following criteria at study entry :
- •Subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study.
- •A male or female between, and including, 18 and 45 years at the time of the first vaccination.
- •Written informed consent obtained from the subject.
- •Healthy subjects as established by medical history, clinical examination and clinical laboratory assessment before entering into the study.
- •If the subject is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.
- •Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly (when applicable, as mentioned in the product label) for example abstinence, combined or progestogen oral contraceptives, injectable progestogen, implants of levonorgestrel, oestrogenic vaginal ring, percutaneous contraceptive patches or intrauterine device (IUD) or intrauterine system (IUS), vasectomy with documented azoospermia of the sole male partner or double barrier method (condom or occlusive cap plus spermicidal agent).
- •For azoospermia, documented” refers to the outcome of the investigator's/designee’s medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject’s medical records.
- •Post-menopause: Menopause is the age associated with complete cessation of menstrual cycles, menses, and implies the loss of reproductive potential by ovarian failure. A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile at the appropriate age e.g. > 45 years.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previous vaccination against Hepatitis B.
- •Positive for anti-HBs antibodies, antiHBc antibodies, HBsAg, HCV antibodies and/or HIV.
- •Any previous administration of MPL® and/or QS21.
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period or participation to another pharmaceutical/vaccine study.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone, or equivalent, =0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine with the exception of the influenza vaccine (pandemic or seasonal) which can be administered > 21 days preceding or > 21 days following each primary vaccine dose (Doses 1 and 2) AND > 7 days preceding or > 7 days following the booster dose. .
- •Administration of immunoglobulins and/or any blood products within the last 3 months.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).
- •Current serious neurologic or mental disease.
- •Any past or current malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders.
- •Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, renal functional abnormality, autoimmune disease or anemia, as determined by physical examination or laboratory screening tests at the discretion of the investigator.
- •Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature <37.5°C.
- •Pregnant or lactating female.
- •History of chronic alcohol consumption and/or drug abuse.
- •Other conditions that the principal investigator judges may interfere with study findings.
研究者
相似试验
进行中（未招募）
不适用
A phase II, randomized, multicentre, observer-blind study to compare and characterize the immunoginicity and safety parameters induced by various GSK Biologicals’ Adjuvant Systems in combination with the Hepatitis B surface antigen (HBsAg), according to a 0, 1 month schedule with a booster at Month 12, in healthy, Hepatitis B virus (HBV) naïve, adults. - EARLY-CLINRES-002EUCTR2008-004455-29-BEGlaxoSmithKline Biologicals710
进行中（未招募）
不适用
A study to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.Influenza, human.EUCTR2015-000176-10-Outside-EU/EEACSL Limited450
进行中（未招募）
不适用
A study to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.EUCTR2014-005183-15-Outside-EU/EEACSL Limited400
进行中（未招募）
不适用
Determination of the anti-psoriatic efficacy of MomeGalen Creme (mometasone furoate 0.1 %) compared to the reference drug Ecural® Fettcreme and to placebo by defined psoriasis parametersSubjects with a stable phase of chronic psoriasis vulgarisMedDRA version: 14.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-003807-39-DEGALENpharma30
进行中（未招募）
1 期
Study to evaluate immunogenicity and safety of GSK Biologicals’ measles, mumps, rubella and varicella (MMRV) freezer-stored (MMRVF) & refrigerator-stored (MMRVR) vaccine formulations vs. ProQuad in infants 12-14 months of age when co-administered with hepatitis A and pneumococcal conjugate vaccines.Healthy volunteers (Use of the candidate MMRV vaccine for immunization of healthy children 12 - 14 months of age against measles, mumps, rubella and varicella).EUCTR2017-000454-18-Outside-EU/EEAGlaxoSmithKline Biologicals1,851